8-K: Coeptis Therapeutics to Restate Past Financials Due to Accounting Errors

Coeptis Therapeutics Holdings, Inc. announced it will restate its financial statements from 2022 and 2023 due to accounting errors related to a merger and a research agreement.

Summary

• Coeptis Therapeutics has determined that its previously issued financial statements for the year ended December 31, 2022, and the quarterly periods ended March 31, June 30, and September 30, 2023, can no longer be relied upon.
• This decision was made by the Audit Committee after discussions with management and the company's independent auditor.
• The restatement is due to an unrecorded liability from the merger with Bull Horn Holdings Corp. in October 2022 and a reimbursement commitment related to a research agreement dated January 25, 2023.
• The unrecorded merger liability has an immaterial remaining balance as of March 22, 2024, and will be paid in 2024.
• No reimbursement payments have been made for the research agreement as of March 22, 2024, but the company expects to receive invoices and make payments in the near future.
• The company plans to file the restated financial statements as soon as practicable.

Sentiment

Score: 3

Explanation: The announcement of a restatement due to accounting errors is a significant negative, indicating potential issues with internal controls and financial reporting. This will likely negatively impact investor confidence.

Positives

• The unrecorded merger liability has an immaterial remaining balance and will be paid in 2024.
• The company has hired a full-time Chief Financial Officer in 2023 to improve internal controls and procedures.
• The company is working to file the restated financial statements as soon as practicable.

Negatives

• The company's previously issued financial statements for 2022 and 2023 can no longer be relied upon.
• There were accounting errors related to the merger with Bull Horn Holdings Corp. and a research agreement.
• The company had weaknesses in its disclosure controls and procedures during 2022 and 2023.

Risks

• The company faces risks related to completing the restatements and addressing material weaknesses.
• There are risks of substantial costs and diversion of personnel attention and resources to address the restatements.
• The company could face litigation or regulatory action due to the restatements.
• There is a risk of reputational damage due to the restatements.
• The restatement could negatively impact the value of the company's common stock.
• The filing of the restated financial statements may take longer than anticipated.

Future Outlook

The company expects to file the restated financial statements as soon as practicable and will make reimbursement payments related to the research agreement in the near future.

Management Comments

• Management concluded that a certain unrecorded liability resulting from the merger with Bull Horn Holdings Corp. should be recorded.
• Management expects that reimbursement requests for each of the quarterly periods during the fiscal year ended December 31, 2023 will be received in the near future and such payments will be made accordingly.
• The company believes the hiring of a full-time Chief Financial Officer has and will continue to provide for improved processes related to controls and procedures.

Industry Context

Restatements of financial statements are not uncommon, but they can raise concerns about a company's internal controls and financial reporting practices. This announcement may lead investors to scrutinize Coeptis's financials more closely.

Comparison to Industry Standards

• Restatements are not unique to Coeptis, but the reasons for the restatement are important to consider.
• Companies like Cassava Sciences and DLocal have also faced scrutiny and restatements due to accounting issues, highlighting the importance of robust internal controls.
• The impact of the restatement on Coeptis will depend on the severity of the errors and the company's ability to remediate the issues quickly and transparently.

Stakeholder Impact

• Shareholders may experience a negative impact on the value of their shares due to the restatement.
• Employees may be affected by the increased workload and scrutiny related to the restatement.
• Creditors may become more cautious about lending to the company.
• Customers and suppliers may have concerns about the company's financial stability.

Next Steps

• The company will file restated financial statements as soon as practicable.
• The company will make reimbursement payments related to the research agreement in the near future.

Key Dates

Keywords

restatement, financial statements, accounting errors, merger, liability, research agreement, internal controls, audit committee, SEC, Coeptis Therapeutics